Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study
Anlotinib is a novel inhibitor of receptor kinase tyrosine with multitargets and has a broad spectrum of inhibitory action on tumor angiogenesis and growth. A simple and rapid UHPLC-MS/MS bioanalytical method was validated for the determination of anlotinib in rat plasma, using imatinib as an intern...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Analytical Methods in Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2019/5016757 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306133042298880 |
|---|---|
| author | Zhe Wang Le-jing Lian Yan-yan Dong Xiao Cui Jian-chang Qian Cheng-ke Huang Rui-jie Chen Wei Sun |
| author_facet | Zhe Wang Le-jing Lian Yan-yan Dong Xiao Cui Jian-chang Qian Cheng-ke Huang Rui-jie Chen Wei Sun |
| author_sort | Zhe Wang |
| collection | DOAJ |
| description | Anlotinib is a novel inhibitor of receptor kinase tyrosine with multitargets and has a broad spectrum of inhibitory action on tumor angiogenesis and growth. A simple and rapid UHPLC-MS/MS bioanalytical method was validated for the determination of anlotinib in rat plasma, using imatinib as an internal standard. An Acquity BEH C18 column was used to separate analytes. The eluents consisted of formic acid/water (0.1 : 100, v/v) and acetonitrile with a mobile phase. A triple quadrupole mass spectrometer was operated for the quantification with multiple reaction monitoring (MRM) to determine transitions: 408.2 ⟶ 339.1 for anlotinib, and 494.3 ⟶ 394.1 for imatinib. The validated range was 0.1–50 ng/mL for anlotinib. Mean recovery rate of anlotinib in plasma was ≥99.32% and reproducible. Also, the intra- and interday precisions were both below 15%. This robust method was successfully applied to support the pharmacokinetic study of anlotinib in rats. |
| format | Article |
| id | doaj-art-3989e973101843e19b1faf4e71a439e9 |
| institution | Kabale University |
| issn | 2090-8865 2090-8873 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Analytical Methods in Chemistry |
| spelling | doaj-art-3989e973101843e19b1faf4e71a439e92025-08-20T03:55:11ZengWileyJournal of Analytical Methods in Chemistry2090-88652090-88732019-01-01201910.1155/2019/50167575016757Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic StudyZhe Wang0Le-jing Lian1Yan-yan Dong2Xiao Cui3Jian-chang Qian4Cheng-ke Huang5Rui-jie Chen6Wei Sun7Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaDepartment of Ultrasonography, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, ChinaDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaAnlotinib is a novel inhibitor of receptor kinase tyrosine with multitargets and has a broad spectrum of inhibitory action on tumor angiogenesis and growth. A simple and rapid UHPLC-MS/MS bioanalytical method was validated for the determination of anlotinib in rat plasma, using imatinib as an internal standard. An Acquity BEH C18 column was used to separate analytes. The eluents consisted of formic acid/water (0.1 : 100, v/v) and acetonitrile with a mobile phase. A triple quadrupole mass spectrometer was operated for the quantification with multiple reaction monitoring (MRM) to determine transitions: 408.2 ⟶ 339.1 for anlotinib, and 494.3 ⟶ 394.1 for imatinib. The validated range was 0.1–50 ng/mL for anlotinib. Mean recovery rate of anlotinib in plasma was ≥99.32% and reproducible. Also, the intra- and interday precisions were both below 15%. This robust method was successfully applied to support the pharmacokinetic study of anlotinib in rats.http://dx.doi.org/10.1155/2019/5016757 |
| spellingShingle | Zhe Wang Le-jing Lian Yan-yan Dong Xiao Cui Jian-chang Qian Cheng-ke Huang Rui-jie Chen Wei Sun Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study Journal of Analytical Methods in Chemistry |
| title | Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study |
| title_full | Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study |
| title_fullStr | Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study |
| title_full_unstemmed | Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study |
| title_short | Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study |
| title_sort | determination of anlotinib a tyrosine kinase inhibitor in rat plasma by uhplc ms ms and its application to a pharmacokinetic study |
| url | http://dx.doi.org/10.1155/2019/5016757 |
| work_keys_str_mv | AT zhewang determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT lejinglian determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT yanyandong determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT xiaocui determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT jianchangqian determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT chengkehuang determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT ruijiechen determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy AT weisun determinationofanlotinibatyrosinekinaseinhibitorinratplasmabyuhplcmsmsanditsapplicationtoapharmacokineticstudy |